COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials
by Bill Snyder AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca. On Oct. 9, AstraZeneca…